Stock Comparison
ABBV vs PAVM
AbbVie Inc vs PAVmed Inc
Who's the better investment? Let's break it down.
The Verdict
PAVM takes this one.
PAVM edges out the competition with a 1.7-point advantage. Not a blowout, but the numbers favor PAVM.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
ABBV
Metric
PAVM
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
Profitability & Growth
ABBV
Metric
PAVM
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
ABBV
Metric
PAVM
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
ABBV
What Could Go Wrong
AbbVie's future growth relies heavily on the continued success and market share expansion of its next-generation immunology drugs, Skyrizi and Rinvoq, which together are projected to reach over $32 bi...
Red Flags
- 🚩Insider Selling Activity: 4 insider sales and 0 purchases in the last 6 months, as per the Quiver so...
- 🚩High R&D Investment for Uncertain Returns: While inherent to pharma, the substantial R&D expenditure...
- 🚩GAAP EPS Volatility: The Q1 2026 GAAP diluted EPS of $0.39, a -45.8% YoY decline due to an unfavorab...
PAVM
What Could Go Wrong
PAVmed Inc. faces immediate and critical financial risk with only $6.5 million in cash against quarterly operating expenses of $8.1 million as of Q1 2026. Failure to secure substantial new funding for...
Red Flags
- 🚩PAVmed Inc. consolidated cash balance of $6.5 million as of Q1 2026 vs. $8.1 million in quarterly op...
- 🚩Persistent high cash burn rate at the parent company without meaningful offsetting revenue generatio...
- 🚩High likelihood of significant future shareholder dilution for PAVmed Inc. common stock, given ongoi...
Competitive Moat
ABBV
Rating
🛡️ Wide
Trend
➡️ Stable
PAVM
Rating
🛡️ None
Trend
📈 Expanding
Investment Thesis
If AbbVie's key immunology drugs, Skyrizi and Rinvoq, continue to expand their market share globally and achieve their projected combined annual revenue of over $32 billion by 2027, complemented by successful advancements in its neuroscience and oncology pipelines, then the company will sustain mid-to-high single-digit revenue growth and generate substantial free cash flow, supporting its robust d...
Full ABBV AnalysisIf PAVmed Inc. successfully secures near-term financing for its parent operations (e.g., $30M+ by Q3 2026) and Lucid Diagnostics significantly accelerates EsoGuard commercialization (e.g., reaching $5M+ quarterly revenue by Q4 2026 with expanding reimbursement) alongside Veris Health achieving FDA 510(k) clearance in late 2026, then the combined entity could see its market capitalization re-rate s...
Full PAVM AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the mature, highly regulated nature of the pharmaceutical industry inherently preclude the possibility of ...
Full ABBV AnalysisPAVmed Inc. remains an extremely speculative investment. While Lucid Diagnostics (a subsidiary) shows nascent commercial progress with $1.3M in Q1 2026 EsoGuard revenue and 3,177 tests processed, PAVmed Inc.'s consolidated financial health is critically weak. The Q1 2026 report reveals only $6.5 million in cash and equivalents against $8.1 million in quarterly operating expenses, implying a cash runway of less than one quarter. This immediate liquidity concern for the parent company, coupled wit...
Full PAVM AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.